EUVIMEDEUVIMED entdecken
Open Access

Comparing HIV Vaccine Immunogenicity Across Trials With Different Populations and Study Designs

Yutong Jin iD, Alex Luedtke iD, Zoe Moodie iD, Holly Janes, David Benkeser

Statistics in Medicine · 2026-04 · 45 (8-9)

DOI: 10.1002/sim.70495 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, online erschienen am 01.04.2026. Verfasst von Yutong Jin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: AIDS Vaccines, HIV Infections, Immunogenicity, Vaccine, Randomized Controlled Trials as Topic. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Safe and effective preventive vaccines have the potential to help stem the HIV epidemic. The efficacy of such vaccines is typically measured in randomized, double‐blind phase IIb/III trials and described as a reduction in newly acquired HIV infections. However, such trials are often expensive, time‐consuming, and/or logistically challenging. These challenges lead to a great interest in immune responses induced by vaccination, and in identifying which immune responses predict vaccine efficacy. These responses are termed vaccine correlates of protection . Studies of vaccine‐induced immunogenicity vary in size and design, ranging from small, early‐phase trials to case‐control studies nested in a broader late‐phase randomized trial. Moreover, trials can be conducted in geographically diverse study populations across the world. Such diversity presents a challenge for objectively comparing vaccine‐induced immunogenicity. To address these practical challenges, we propose a framework that is capable of identifying appropriate causal estimands and estimators, which can be used to provide standardized comparisons of vaccine‐induced immunogenicity across trials. We evaluate the performance of the proposed estimands via extensive simulation studies. Our estimators are well‐behaved and enjoy robustness properties. The proposed technique is applied to compare vaccine immunogenicity using data from three recent HIV vaccine trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AIDS VaccinesHIV InfectionsImmunogenicity, VaccineRandomized Controlled Trials as TopicHumansVaccine EfficacyResearch DesignComputer SimulationDouble-Blind Method

Stichwörter der Autor:innen

HIV/AIDScausal inferenceinfectious diseaserandomized clinical trialsvaccine immunogenicity

Substanzen

AIDS Vaccines

Autor:innen und Institutionen

  • Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia, USA.
  • Department of Statistics, University of Washington, Seattle, Washington, USA.
  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

ORCID-Profile: Yutong Jin, Alex Luedtke, Zoe Moodie

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Jin, Y., Luedtke, A., Moodie, Z., Janes, H., & Benkeser, D. (2026). Comparing HIV Vaccine Immunogenicity Across Trials With Different Populations and Study Designs. Statistics in Medicine, 45(8-9). https://doi.org/10.1002/sim.70495

Vancouver

Jin Y, Luedtke A, Moodie Z, Janes H, Benkeser D. Comparing HIV Vaccine Immunogenicity Across Trials With Different Populations and Study Designs. Statistics in Medicine. 2026;45(8-9). doi:10.1002/sim.70495

BibTeX
@article{Jin2026,
  author = {Jin, Yutong and Luedtke, Alex and Moodie, Zoe and Janes, Holly and Benkeser, David},
  title = {Comparing HIV Vaccine Immunogenicity Across Trials With Different Populations and Study Designs},
  journal = {Statistics in Medicine},
  year = {2026},
  volume = {45},
  number = {8-9},
  doi = {10.1002/sim.70495}
}
Kostenlos starten →